Bayer: signs agreement with MOMA in oncology

(CercleFinance.com) - Bayer and MOMA Therapeutics have signed an option and exclusive license agreement to develop and commercialize a small molecule oncology program based on MOMA's proprietary KNOMATIC platform.


As part of the agreement, Bayer will be responsible for further preclinical, development and commercial activities.

As part of the agreement, Bayer will have access to the program itself, as well as to the results generated via MOMA's KNOMATIC platform.

Dynamic proteins represent an emerging class of therapeutic targets that may play a critical role in disease progression. Targeting these proteins via a small molecule approach offers a largely untapped means of developing innovative cancer therapies' says the group.

' We are delighted to partner with MOMA Therapeutics to explore the untapped potential of highly dynamic proteins in oncology', said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer's Pharmaceutical Division.

' This collaboration reinforces Bayer's commitment to precision medicine while enhancing our ability to address significant unmet medical needs in cancer treatment.

Copyright (c) 2024 CercleFinance.com. All rights reserved.